Table 1.
Item No. | TNF-α | IL-6 | INF-γ | Dexa | COX2 | iNOS | Item No. | TNF-α | IL-6 | INF-γ | Dexa | COX2 | iNOS |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Qing Re Xie Huo (9) | Qing Re Jie Du (27) | ||||||||||||
1 | — | ↑ | ↓ | — | ↓ | ↓ | 28 | ↓ | — | ↓ | — | ↓ | ↓ |
2 | — | — | — | — | ↓ | ↓ | 29 | ↓ | ↓ | ↓ | ↓ | ↓ | — |
3 | — | ↓ | — | — | — | ↓ | 30 | — | ↓ | ↓ | — | ↓ | ↓ |
4 | — | — | — | — | — | — | 31 | — | — | — | — | ↓ | ↓ |
5 | — | ↓ | ↓ | — | ↓ | ↓ | 32 | — | — | — | — | ↓ | — |
6 | — | — | — | — | ↓ | — | 33 | — | — | — | — | — | ↓ |
7 | — | — | — | — | ↓ | — | 34 | — | — | — | — | ↓ | ↓ |
8 | — | ↓ | ↓ | ↓ | ↓ | ↓ | 35 | — | ↑↓ | — | — | ↓ | ↓ |
9 | — | — | — | — | — | ↓ | 36 | — | — | ↓ | ↑ | — | ↓ |
Qing Re Zhao Shi (7) | 37 | — | ↓ | ↓ | — | — | ↓ | ||||||
10 | ↓ | ↑↓ | ↓ | ↓ | ↓ | — | 38 | — | — | — | — | ↓ | — |
11 | — | ↓ | ↓ | — | ↓ | — | 39 | — | — | ↓ | — | — | ↓ |
12 | — | ↓ | — | — | — | ↓ | 40 | — | — | ↓ | — | ↓ | ↓ |
13 | — | — | — | — | — | — | 41 | — | — | ↓ | — | — | ↓ |
14 | — | ↓ | — | — | ↓ | ↓ | 42 | — | — | ↓ | — | ↓ | ↓ |
15 | — | — | — | — | — | — | 43 | — | ↑ | — | — | ↓ | — |
16 | — | — | — | — | ↓ | — | 44 | — | — | — | — | — | ↓ |
Qing Re Liang Xue (5) | 45 | — | — | ↓ | — | — | — | ||||||
17 | — | — | — | — | ↓ | ↓ | 46 | — | ↓ | — | — | — | ↓ |
18 | — | — | ↓ | — | — | ↓ | 47 | — | — | — | — | ↓ | ↓ |
19 | ↓ | ↓ | ↓ | ↓ | — | ↓ | 48 | ↓ | ↓ | ↓ | ↓ | ↓ | — |
20 | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | 49 | — | — | — | — | — | — |
21 | — | — | — | ↓ | ↓ | ↓ | 50 | — | — | — | — | ↓ | — |
Qing Xu Re (6) | 51 | — | ↓ | ↓ | — | — | ↓ | ||||||
22 | — | — | ↓ | — | ↓ | — | 52 | — | — | — | — | ↓ | ↓ |
23 | ↓ | ↓ | ↓ | ↓ | — | — | 53 | — | — | — | — | ↓ | — |
24 | — | ↑↓ | — | — | ↓ | ↓ | 54 | — | ↓ | ↓ | — | ↓ | ↓ |
25 | — | — | — | ↑ | ↓ | — | |||||||
26 | — | — | ↓ | — | ↓ | ↓ | |||||||
27 | — | ↓ | ↓ | — | — | ↓ |
TNF-α: TNF-α-NFκB luciferase reporter; IL-6: IL-6-STAT3 luciferase reporter; INF-γ: INFγ-GAS luciferase reporter; Dexa: Dexamethasone-GRE luciferase reporter; COX2: COX2 enzyme activity; iNOS: iNOS enzyme activity. ↓: inhibition ≥ 50%; ↑: stumulation ≥ 3 folds; —: no impact w/o β-glucuronidase treatment at concentration ≤ 750 µg/ml in the inflammatory cytokine or glucocorticoid signaling pathway and at concentration ≤ 4 mg/ml in COX2, iNOS enzyme activity assay.